Abstract
Superantigens (SAgs) are extremely potent bacterial toxins, which evoke a virulent immune response, inducing nonspecific T-cell proliferation, rapid cytokine release, and lethal toxic shock, for which there is no effective treatment. We previously developed a small molecule, S101, which potently inhibits proliferating T cells. In a severe mouse model of toxic shock, a single injection of S101 given together with superantigen challenge rescued 100% of the mice. Even when given 2 hours after challenge, S101 rescued 40% of the mice. S101 targets the T-cell receptor, inflammatory response, and actin cytoskeleton pathways. S101 inhibits the aryl hydrocarbon receptor, a ligand-activated transcription factor that is involved in the differentiation of T-helper cells, especially Th17, and regulatory T cells. Our results provide the rationale for developing S101 to treat superantigen-induced toxic shock and other pathologies characterized by T-cell activation and proliferation.
Original language | English |
---|---|
Pages (from-to) | 288-297 |
Number of pages | 10 |
Journal | Journal of Infectious Diseases |
Volume | 217 |
Issue number | 2 |
Early online date | 15 Nov 2017 |
DOIs | |
State | Published - 15 Jan 2018 |
Externally published | Yes |
Keywords
- T-cell
- aryl hydrocarbon receptor
- inflammation
- superantigen
- toxic shock
All Science Journal Classification (ASJC) codes
- Immunology and Allergy
- Infectious Diseases